Universal Diagnostics is a biomedicine start-up focused on the development of leading edge technologies in metabolomics, genetics and bioinformatics, with the mission to develop a blood test for early detection.
Seleziona la regione che meglio si adatta alla tua posizione o alle tue preferenze.
Questa impostazione controlla la lingua dell'interfaccia utente, inclusi i pulsanti, i menu e tutto il testo del sito. Seleziona la tua lingua preferita per la migliore esperienza di navigazione.
Seleziona le lingue per gli annunci di lavoro che desideri vedere. Questa impostazione determina quali annunci di lavoro ti verranno mostrati.
Universal Diagnostics is a biomedicine start-up focused on the development of leading edge technologies in metabolomics, genetics and bioinformatics, with the mission to develop a blood test for early detection.
The seed of Universal Diagnostics (UDX) was born at NASA Ames Park, in Mountain View, California, during the summer of 2012. Following SingularityUniversity’s global challenge to impact positively one billion people, two experienced technology entrepreneurs decided to launch together a bio-medicine start-up with the goal of fighting Humanity’s most important enemy: cancer.
The company was officially incorporated in Spain.
The monumental goal of UDX is to develop a test to detect cancer early, when it still can be cured and save millions of lives.
The company closed a seed round of capital from international investors.
UDX started a large-scale research metabolomics project for discovering ex-novo biomarkers for different cancers with high incidence and mortality rate in the world.
UDX has established alliances and collaborations with international universities, companies, biobanks and hospitals to validate the technology in all races and populations.
Following clinical trials and regulatory approval, UDX will offer tests for the early diagnostics of the most prevalent cancers.
UDX’s first product is a blood-based test for the early detection of colorectal cancer and polyps, the precursor to colorectal cancer.